2017 American Transplant Congress
Early and Late Antibody Mediated Rejection and Mixed Acute Rejection Are Clinically Distinct and Demonstrate Biologic Differences in Immunodominant Donor Specific Antibody Characteristics.
1U of Cincinnati, Cincinnati; 2The Christ Hospital, Cincinnati
Early and late antibody mediated rejection (AMR) and mixed acute rejection (MAR) possibly result from fundamentally different immunologic processes. DSA mediates direct injury by complement-dependent…2017 American Transplant Congress
HLA Donor-Specific Antibody (DSA) Negative Antibody-Mediated Rejection (AMR): Incidence, Treatment and Outcomes.
Background: Banff 2013 criteria for the diagnosis of antibody-meditated rejection (AMR) in kidney transplants require the presence of donor-specific antibody (DSA). Clinical significance of histological…2017 American Transplant Congress
Tocilizmab (Anti-IL-6R) Treatment (TCZ-Rx) Reduced Total IgG Levels Including Anti-HLA IgG: Analysis of IgG Subclasses (IgG1-IgG4) and Anti-HLA IgG Subclasses Show Similar Reductions in All Subclasses from Patients with DSA+ Chronic Antibody-Mediated Rejection (CABMR).
Background: DSA+ CABMR constitutes the major cause for renal allograft loss in the U.S. Currently there are no approved therapies. We have reported TCZ use…2017 American Transplant Congress
A Novel Role for MyD88 Signaling Downstream from Toll-Like Receptors in B Cells Responding to Blood Group Antigens.
Hiroshima University, Hiroshima, Japan
[Introduction]Although there is some empirical evidence that severe infectious complications provoke refractory AMR following ABO-incompatible transplantations (ABOi-Tx), its mechanism remains unclear. Here, we investigated a…2017 American Transplant Congress
A Prospective Iterative Trial of Carfizomib-Based Desensitization Trial: Initial Comparative Observations.
1U of Cincinnati, Cincinnati; 2Christ Hospital, Cincinnati
Carfilzomib (CFZ) is a 2nd generation proteasome inhibitor different form bortezomib in that it irreversibly disables 20s and 26s proteasomes.Results from the first 2 phases…2017 American Transplant Congress
Improved Outcome of Kidney Transplants by Donor Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes.
Introduction: De novo donor-specific HLA antibodies (dnDSA) are recognized as a risk factor for graft loss. Determinants of DSA specificity are generated via the indirect…2017 American Transplant Congress
Percentage of CD19+ B Cells as a Predictor of Acute Antibody-Mediated Rejection After Administration of Rituximab in ABO-Incompatible Kidney Transplantation.
Urology, Hokkaido University, Sapporo, Japan
[Introduction] Administration of rituximab to ABO-incompatible kidney transplant (ABOi-KTx) recipients is recognized as effective and safe. A single dose of 375 mg/m2 rituximab is generally…2017 American Transplant Congress
Preformed HLA Donor-Specific Antibodies Disappearance After Kidney Transplantation: Significance and Comparison with Persistent DSA.
The presence of donor-specific antibodies (DSA) increase the risk of antibody-mediated rejection (ABMR) and graft failure in kidney transplant recipients (KTR). We aimed to analyze…2017 American Transplant Congress
A-Antigen (Ag)-Specific Tolerance Following A-Ag Administration to Infant Mice.
Purpose: In contrast to adults, ABO-incompatible heart transplantation (ABOi HTx) can safely be performed in infants due to absent/low levels of anti-A/B antibodies (Ab). Tolerance…2017 American Transplant Congress
Antibody Mapping by Protein Microarray Revealed a Unique Repertoire in Lung Transplant Recipients That Developed Chronic Lung Allograft Dysfunction.
Background: Development of chronic lung allograft dysfunction (CLAD) limits long-term success from lung transplantation (LTx). Elicitation of de novo antibody (Ab) to mismatched donor HLA…
- « Previous Page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- …
- 57
- Next Page »